I'm LongbridgeAI, I can summarize articles.On Monday, Avidity Biosciences opened with a surge of over 42%, reaching a historic high of $70.13. In terms of news, Swiss pharmaceutical company NOVARTIS AG has agreed to acquire the American biotechnology company Avidity Biosciences, with the acquisition deal valued at $12 billion. NOVARTIS AG stated that it will acquire shares at a cash price of $72 per share, which represents a 46% premium over Avidity's closing price on Friday. The company also mentioned that the equity value of the transaction is $12 billion, but after the deal is completed, Avidity is expected to have approximately $1 billion in cash, bringing its enterprise value to about $11 billion. This makes it NOVARTIS AG's largest acquisition in nearly a decade. The entire transaction is expected to be completed in the first half of 2026, but is contingent upon the completion of the spin-off matters
According to Zhitong Finance APP, on Monday, Avidity Biosciences (RNA.US) opened with a surge of over 42%, reaching a historic high of $70.13. In terms of news, Swiss pharmaceutical company Novartis AG (NVS.US) has agreed to acquire the American biotechnology company Avidity Biosciences, with the acquisition valued at $12 billion. Novartis stated that it will purchase shares at a cash price of $72 each, which represents a 46% premium over Avidity's closing price on Friday.
Novartis also mentioned that the equity value of the transaction is $12 billion, but after the deal is completed, Avidity is expected to have approximately $1 billion in cash, bringing its enterprise value to about $11 billion. This makes it Novartis's largest acquisition in nearly a decade. The entire transaction is expected to be completed in the first half of 2026, but is contingent upon the completion of the spin-off matters